High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial

HIV is usually associated with weight loss. World health Organization (WHO) recommends early antiretroviral (ART) initiation, but data on the progression of body mass index (BMI) in participants initiating early ART in Africa are scarce. The Temprano randomized trial was conducted in Abidjan to asse...

Full description

Saved in:
Bibliographic Details
Published in:AIDS research and therapy 2016-02, Vol.13 (12), p.12-12, Article 12
Main Authors: Guehi, Calixte, Badjé, Anani, Gabillard, Delphine, Ouattara, Eric, Koulé, Serge Olivier, Moh, Raoul, Ekouevi, Didier, Ahibo, Hugues, N'Takpé, Jean Baptiste, Menan, Gérard Kouamé, Deschamps, Nina, Lecarrou, Jerôme, Eholié, Serge, Anglaret, Xavier, Danel, Christine
Format: Article
Language:English
Subjects:
Adult
AIDS/HIV
Analysis
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
Antitubercular Agents - therapeutic use
Antiviral agents
Body Mass Index
Clinical trials
Cote d'Ivoire - epidemiology
Drug therapy
Female
Health aspects
HIV
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Isoniazid - therapeutic use
Life Sciences
Male
Obesity
Obesity - complications
Obesity - epidemiology
Overweight - complications
Overweight - epidemiology
Tuberculosis, Pulmonary - prevention & control
Weight
Weight Loss - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c526t-a5b4624c0d6e7b94a711ecb2b9002cf1cb32d522712d242aca95638c840e4abd3
cites cdi_FETCH-LOGICAL-c526t-a5b4624c0d6e7b94a711ecb2b9002cf1cb32d522712d242aca95638c840e4abd3
container_end_page 12
container_issue 12
container_start_page 12
container_title AIDS research and therapy
container_volume 13
creator Guehi, Calixte
Badjé, Anani
Gabillard, Delphine
Ouattara, Eric
Koulé, Serge Olivier
Moh, Raoul
Ekouevi, Didier
Ahibo, Hugues
N'Takpé, Jean Baptiste
Menan, Gérard Kouamé
Deschamps, Nina
Lecarrou, Jerôme
Eholié, Serge
Anglaret, Xavier
Danel, Christine
description HIV is usually associated with weight loss. World health Organization (WHO) recommends early antiretroviral (ART) initiation, but data on the progression of body mass index (BMI) in participants initiating early ART in Africa are scarce. The Temprano randomized trial was conducted in Abidjan to assess the effectiveness of early ART and Isoniazid (INH) prophylaxis for tuberculosis in HIV-infected persons with high CD4 counts below 800 cells/mm(3) without any indication for starting ART. Patients initiating early ART before December 2010 were included in this sub-study. BMI was categorized as: underweight (
doi_str_mv 10.1186/s12981-016-0094-y
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4768327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A444333705</galeid><sourcerecordid>A444333705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-a5b4624c0d6e7b94a711ecb2b9002cf1cb32d522712d242aca95638c840e4abd3</originalsourceid><addsrcrecordid>eNptkt9u0zAUxiMEYmPwANwgS0gIpGX4X5zmBqmagFarKBqFW8txThpPid3ZSaEPwTvwLDwZLt1GOyFf2LJ_33esc74keU7wGSEj8TYQWoxIiolIMS54unmQHJOc01RwnD3cOx8lT0K4wpgJSrLHyREVBc1Ilh0nPydm2aCVh7VqwWpArkYlGLtE8zX47xBfe6RsheYlBECT6bfU2Bp0DxVagQ_OhtMoqJ2Hv5iqe_CI8t-_Omf7JiBnESjfbtD4coGMRX0DaPzp8gsilDCBFtCtvLIOLbxR7dPkUa3aAM9u9pPk64f3i_NJOpt_nJ6PZ6nOqOhTlZVcUK5xJSAvC65yQkCXtCwwpromumS0yijNCa0op0qrIhNspEccA1dlxU6Sdzvf1VB2UGmwvVetXHnTKb-RThl5-GJNI5duLXkuRozm0eB0Z9Dck03GM2lsAN9JTBjddnlNIv76pp531wOEXnYmaGhbZcENQZJcFIIUhLKIvryHXrnB29iNSOVMYI5p9o9axrHFgrWL39RbUznmnDPGcrylzv5DxVVBZ7SzUJt4fyB4cyCITA8_-qUaQpAXn6eH7Ks9tgHVxnG7duhNzMQhSHag9i4ED_VdwwiW2xzLXY5jw4Tc5lhuoubF_oDuFLfBZX8ATkzqGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1773604025</pqid></control><display><type>article</type><title>High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Guehi, Calixte ; Badjé, Anani ; Gabillard, Delphine ; Ouattara, Eric ; Koulé, Serge Olivier ; Moh, Raoul ; Ekouevi, Didier ; Ahibo, Hugues ; N'Takpé, Jean Baptiste ; Menan, Gérard Kouamé ; Deschamps, Nina ; Lecarrou, Jerôme ; Eholié, Serge ; Anglaret, Xavier ; Danel, Christine</creator><creatorcontrib>Guehi, Calixte ; Badjé, Anani ; Gabillard, Delphine ; Ouattara, Eric ; Koulé, Serge Olivier ; Moh, Raoul ; Ekouevi, Didier ; Ahibo, Hugues ; N'Takpé, Jean Baptiste ; Menan, Gérard Kouamé ; Deschamps, Nina ; Lecarrou, Jerôme ; Eholié, Serge ; Anglaret, Xavier ; Danel, Christine</creatorcontrib><description>HIV is usually associated with weight loss. World health Organization (WHO) recommends early antiretroviral (ART) initiation, but data on the progression of body mass index (BMI) in participants initiating early ART in Africa are scarce. The Temprano randomized trial was conducted in Abidjan to assess the effectiveness of early ART and Isoniazid (INH) prophylaxis for tuberculosis in HIV-infected persons with high CD4 counts below 800 cells/mm(3) without any indication for starting ART. Patients initiating early ART before December 2010 were included in this sub-study. BMI was categorized as: underweight (&lt;18.5 kg/m(2)), normal weight (18.5-24.9 kg/m(2)), overweight (25-29.9 kg/m(2)) and obese (≥30 kg/m(2)). At baseline and after 24 months of ART, prevalence of being overweight or obese and factors associated with being overweight or obese were estimated using univariate and multivariate logistic regression. At baseline, 755 participants (78 % women; median CD4 count 442/mm(3), median baseline BMI 22 kg/m(2)) initiated ART. Among them, 19.7 % were overweight, and 7.2 % were obese at baseline. Factors associated with being overweight or obese were: female sex aOR 2.3 (95 % CI 1.4-3.7), age, aOR for 5 years 1.01 (95 % CI 1.0-1.2), high living conditions aOR 2.6 (95 % CI 1.5-4.4), High blood pressure aOR 4.3 (95 % CI 2.0-9.2), WHO stage 2vs1 aOR 0.7 (95 % CI 0.4-1.0) and Hemoglobin ≥95 g/dl aOR 3.0 (95 % CI 1.6-5.8). Among the 597 patients who attended the M24 visit, being overweight or obese increased from 20.4 to 24.8 % (p = 0.01) and 7.2 to 9.2 % (p = 0.03) respectively and factor associated with being overweight or obese was immunological response measured as an increase of CD4 cell count between M0-M24 (for +50 cells/mm(3): aOR 1.01; 95 % CI 1.05-1.13, p = 0.01). The weight categories overweight and obese are highly prevalent in HIV-infected persons with high CD4 cell counts at baseline, and increased over 24 months on ART in this Sub-Saharan African population.</description><identifier>ISSN: 1742-6405</identifier><identifier>EISSN: 1742-6405</identifier><identifier>DOI: 10.1186/s12981-016-0094-y</identifier><identifier>PMID: 26925155</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; AIDS/HIV ; Analysis ; Anti-HIV Agents - therapeutic use ; Antiretroviral drugs ; Antitubercular Agents - therapeutic use ; Antiviral agents ; Body Mass Index ; Clinical trials ; Cote d'Ivoire - epidemiology ; Drug therapy ; Female ; Health aspects ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Isoniazid - therapeutic use ; Life Sciences ; Male ; Obesity ; Obesity - complications ; Obesity - epidemiology ; Overweight - complications ; Overweight - epidemiology ; Tuberculosis, Pulmonary - prevention &amp; control ; Weight ; Weight Loss - drug effects</subject><ispartof>AIDS research and therapy, 2016-02, Vol.13 (12), p.12-12, Article 12</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>Attribution</rights><rights>Guehi et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-a5b4624c0d6e7b94a711ecb2b9002cf1cb32d522712d242aca95638c840e4abd3</citedby><cites>FETCH-LOGICAL-c526t-a5b4624c0d6e7b94a711ecb2b9002cf1cb32d522712d242aca95638c840e4abd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768327/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1773604025?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26925155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-01322515$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Guehi, Calixte</creatorcontrib><creatorcontrib>Badjé, Anani</creatorcontrib><creatorcontrib>Gabillard, Delphine</creatorcontrib><creatorcontrib>Ouattara, Eric</creatorcontrib><creatorcontrib>Koulé, Serge Olivier</creatorcontrib><creatorcontrib>Moh, Raoul</creatorcontrib><creatorcontrib>Ekouevi, Didier</creatorcontrib><creatorcontrib>Ahibo, Hugues</creatorcontrib><creatorcontrib>N'Takpé, Jean Baptiste</creatorcontrib><creatorcontrib>Menan, Gérard Kouamé</creatorcontrib><creatorcontrib>Deschamps, Nina</creatorcontrib><creatorcontrib>Lecarrou, Jerôme</creatorcontrib><creatorcontrib>Eholié, Serge</creatorcontrib><creatorcontrib>Anglaret, Xavier</creatorcontrib><creatorcontrib>Danel, Christine</creatorcontrib><title>High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial</title><title>AIDS research and therapy</title><addtitle>AIDS Res Ther</addtitle><description>HIV is usually associated with weight loss. World health Organization (WHO) recommends early antiretroviral (ART) initiation, but data on the progression of body mass index (BMI) in participants initiating early ART in Africa are scarce. The Temprano randomized trial was conducted in Abidjan to assess the effectiveness of early ART and Isoniazid (INH) prophylaxis for tuberculosis in HIV-infected persons with high CD4 counts below 800 cells/mm(3) without any indication for starting ART. Patients initiating early ART before December 2010 were included in this sub-study. BMI was categorized as: underweight (&lt;18.5 kg/m(2)), normal weight (18.5-24.9 kg/m(2)), overweight (25-29.9 kg/m(2)) and obese (≥30 kg/m(2)). At baseline and after 24 months of ART, prevalence of being overweight or obese and factors associated with being overweight or obese were estimated using univariate and multivariate logistic regression. At baseline, 755 participants (78 % women; median CD4 count 442/mm(3), median baseline BMI 22 kg/m(2)) initiated ART. Among them, 19.7 % were overweight, and 7.2 % were obese at baseline. Factors associated with being overweight or obese were: female sex aOR 2.3 (95 % CI 1.4-3.7), age, aOR for 5 years 1.01 (95 % CI 1.0-1.2), high living conditions aOR 2.6 (95 % CI 1.5-4.4), High blood pressure aOR 4.3 (95 % CI 2.0-9.2), WHO stage 2vs1 aOR 0.7 (95 % CI 0.4-1.0) and Hemoglobin ≥95 g/dl aOR 3.0 (95 % CI 1.6-5.8). Among the 597 patients who attended the M24 visit, being overweight or obese increased from 20.4 to 24.8 % (p = 0.01) and 7.2 to 9.2 % (p = 0.03) respectively and factor associated with being overweight or obese was immunological response measured as an increase of CD4 cell count between M0-M24 (for +50 cells/mm(3): aOR 1.01; 95 % CI 1.05-1.13, p = 0.01). The weight categories overweight and obese are highly prevalent in HIV-infected persons with high CD4 cell counts at baseline, and increased over 24 months on ART in this Sub-Saharan African population.</description><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Analysis</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral drugs</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Antiviral agents</subject><subject>Body Mass Index</subject><subject>Clinical trials</subject><subject>Cote d'Ivoire - epidemiology</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health aspects</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Isoniazid - therapeutic use</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - epidemiology</subject><subject>Overweight - complications</subject><subject>Overweight - epidemiology</subject><subject>Tuberculosis, Pulmonary - prevention &amp; control</subject><subject>Weight</subject><subject>Weight Loss - drug effects</subject><issn>1742-6405</issn><issn>1742-6405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkt9u0zAUxiMEYmPwANwgS0gIpGX4X5zmBqmagFarKBqFW8txThpPid3ZSaEPwTvwLDwZLt1GOyFf2LJ_33esc74keU7wGSEj8TYQWoxIiolIMS54unmQHJOc01RwnD3cOx8lT0K4wpgJSrLHyREVBc1Ilh0nPydm2aCVh7VqwWpArkYlGLtE8zX47xBfe6RsheYlBECT6bfU2Bp0DxVagQ_OhtMoqJ2Hv5iqe_CI8t-_Omf7JiBnESjfbtD4coGMRX0DaPzp8gsilDCBFtCtvLIOLbxR7dPkUa3aAM9u9pPk64f3i_NJOpt_nJ6PZ6nOqOhTlZVcUK5xJSAvC65yQkCXtCwwpromumS0yijNCa0op0qrIhNspEccA1dlxU6Sdzvf1VB2UGmwvVetXHnTKb-RThl5-GJNI5duLXkuRozm0eB0Z9Dck03GM2lsAN9JTBjddnlNIv76pp531wOEXnYmaGhbZcENQZJcFIIUhLKIvryHXrnB29iNSOVMYI5p9o9axrHFgrWL39RbUznmnDPGcrylzv5DxVVBZ7SzUJt4fyB4cyCITA8_-qUaQpAXn6eH7Ks9tgHVxnG7duhNzMQhSHag9i4ED_VdwwiW2xzLXY5jw4Tc5lhuoubF_oDuFLfBZX8ATkzqGQ</recordid><startdate>20160225</startdate><enddate>20160225</enddate><creator>Guehi, Calixte</creator><creator>Badjé, Anani</creator><creator>Gabillard, Delphine</creator><creator>Ouattara, Eric</creator><creator>Koulé, Serge Olivier</creator><creator>Moh, Raoul</creator><creator>Ekouevi, Didier</creator><creator>Ahibo, Hugues</creator><creator>N'Takpé, Jean Baptiste</creator><creator>Menan, Gérard Kouamé</creator><creator>Deschamps, Nina</creator><creator>Lecarrou, Jerôme</creator><creator>Eholié, Serge</creator><creator>Anglaret, Xavier</creator><creator>Danel, Christine</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>KPI</scope><scope>3V.</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope></search><sort><creationdate>20160225</creationdate><title>High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial</title><author>Guehi, Calixte ; Badjé, Anani ; Gabillard, Delphine ; Ouattara, Eric ; Koulé, Serge Olivier ; Moh, Raoul ; Ekouevi, Didier ; Ahibo, Hugues ; N'Takpé, Jean Baptiste ; Menan, Gérard Kouamé ; Deschamps, Nina ; Lecarrou, Jerôme ; Eholié, Serge ; Anglaret, Xavier ; Danel, Christine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-a5b4624c0d6e7b94a711ecb2b9002cf1cb32d522712d242aca95638c840e4abd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Analysis</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral drugs</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Antiviral agents</topic><topic>Body Mass Index</topic><topic>Clinical trials</topic><topic>Cote d'Ivoire - epidemiology</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health aspects</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Isoniazid - therapeutic use</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - epidemiology</topic><topic>Overweight - complications</topic><topic>Overweight - epidemiology</topic><topic>Tuberculosis, Pulmonary - prevention &amp; control</topic><topic>Weight</topic><topic>Weight Loss - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guehi, Calixte</creatorcontrib><creatorcontrib>Badjé, Anani</creatorcontrib><creatorcontrib>Gabillard, Delphine</creatorcontrib><creatorcontrib>Ouattara, Eric</creatorcontrib><creatorcontrib>Koulé, Serge Olivier</creatorcontrib><creatorcontrib>Moh, Raoul</creatorcontrib><creatorcontrib>Ekouevi, Didier</creatorcontrib><creatorcontrib>Ahibo, Hugues</creatorcontrib><creatorcontrib>N'Takpé, Jean Baptiste</creatorcontrib><creatorcontrib>Menan, Gérard Kouamé</creatorcontrib><creatorcontrib>Deschamps, Nina</creatorcontrib><creatorcontrib>Lecarrou, Jerôme</creatorcontrib><creatorcontrib>Eholié, Serge</creatorcontrib><creatorcontrib>Anglaret, Xavier</creatorcontrib><creatorcontrib>Danel, Christine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Global Issues</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AIDS research and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guehi, Calixte</au><au>Badjé, Anani</au><au>Gabillard, Delphine</au><au>Ouattara, Eric</au><au>Koulé, Serge Olivier</au><au>Moh, Raoul</au><au>Ekouevi, Didier</au><au>Ahibo, Hugues</au><au>N'Takpé, Jean Baptiste</au><au>Menan, Gérard Kouamé</au><au>Deschamps, Nina</au><au>Lecarrou, Jerôme</au><au>Eholié, Serge</au><au>Anglaret, Xavier</au><au>Danel, Christine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial</atitle><jtitle>AIDS research and therapy</jtitle><addtitle>AIDS Res Ther</addtitle><date>2016-02-25</date><risdate>2016</risdate><volume>13</volume><issue>12</issue><spage>12</spage><epage>12</epage><pages>12-12</pages><artnum>12</artnum><issn>1742-6405</issn><eissn>1742-6405</eissn><abstract>HIV is usually associated with weight loss. World health Organization (WHO) recommends early antiretroviral (ART) initiation, but data on the progression of body mass index (BMI) in participants initiating early ART in Africa are scarce. The Temprano randomized trial was conducted in Abidjan to assess the effectiveness of early ART and Isoniazid (INH) prophylaxis for tuberculosis in HIV-infected persons with high CD4 counts below 800 cells/mm(3) without any indication for starting ART. Patients initiating early ART before December 2010 were included in this sub-study. BMI was categorized as: underweight (&lt;18.5 kg/m(2)), normal weight (18.5-24.9 kg/m(2)), overweight (25-29.9 kg/m(2)) and obese (≥30 kg/m(2)). At baseline and after 24 months of ART, prevalence of being overweight or obese and factors associated with being overweight or obese were estimated using univariate and multivariate logistic regression. At baseline, 755 participants (78 % women; median CD4 count 442/mm(3), median baseline BMI 22 kg/m(2)) initiated ART. Among them, 19.7 % were overweight, and 7.2 % were obese at baseline. Factors associated with being overweight or obese were: female sex aOR 2.3 (95 % CI 1.4-3.7), age, aOR for 5 years 1.01 (95 % CI 1.0-1.2), high living conditions aOR 2.6 (95 % CI 1.5-4.4), High blood pressure aOR 4.3 (95 % CI 2.0-9.2), WHO stage 2vs1 aOR 0.7 (95 % CI 0.4-1.0) and Hemoglobin ≥95 g/dl aOR 3.0 (95 % CI 1.6-5.8). Among the 597 patients who attended the M24 visit, being overweight or obese increased from 20.4 to 24.8 % (p = 0.01) and 7.2 to 9.2 % (p = 0.03) respectively and factor associated with being overweight or obese was immunological response measured as an increase of CD4 cell count between M0-M24 (for +50 cells/mm(3): aOR 1.01; 95 % CI 1.05-1.13, p = 0.01). The weight categories overweight and obese are highly prevalent in HIV-infected persons with high CD4 cell counts at baseline, and increased over 24 months on ART in this Sub-Saharan African population.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>26925155</pmid><doi>10.1186/s12981-016-0094-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1742-6405
ispartof AIDS research and therapy, 2016-02, Vol.13 (12), p.12-12, Article 12
issn 1742-6405
1742-6405
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4768327
source Publicly Available Content Database; PubMed Central
subjects Adult
AIDS/HIV
Analysis
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
Antitubercular Agents - therapeutic use
Antiviral agents
Body Mass Index
Clinical trials
Cote d'Ivoire - epidemiology
Drug therapy
Female
Health aspects
HIV
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Isoniazid - therapeutic use
Life Sciences
Male
Obesity
Obesity - complications
Obesity - epidemiology
Overweight - complications
Overweight - epidemiology
Tuberculosis, Pulmonary - prevention & control
Weight
Weight Loss - drug effects
title High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A04%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20prevalence%20of%20being%20Overweight%20and%20Obese%20HIV-infected%20persons,%20before%20and%20after%2024%C2%A0months%20on%20early%20ART%20in%20the%20ANRS%2012136%20Temprano%20Trial&rft.jtitle=AIDS%20research%20and%20therapy&rft.au=Guehi,%20Calixte&rft.date=2016-02-25&rft.volume=13&rft.issue=12&rft.spage=12&rft.epage=12&rft.pages=12-12&rft.artnum=12&rft.issn=1742-6405&rft.eissn=1742-6405&rft_id=info:doi/10.1186/s12981-016-0094-y&rft_dat=%3Cgale_pubme%3EA444333705%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c526t-a5b4624c0d6e7b94a711ecb2b9002cf1cb32d522712d242aca95638c840e4abd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1773604025&rft_id=info:pmid/26925155&rft_galeid=A444333705&rfr_iscdi=true